Published on May 21, 2013 at 9:03 AM
Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical trial of its Symphony CGM System has received Institutional Review Board (IRB) approval. The IRB approval enables the commencement of a clinical evaluation of Symphony that will support the Company's CE Mark Technical File.
"It's gratifying to see this important technology advance. This IRB approval signals a long-awaited CE Mark regulatory trial initiation," commented Dr. Mooney. "Our team's hard work and extreme dedication have put us in a very strong position to begin the process of securing Symphony's market approval by European regulatory agencies."
SOURCE Echo Therapeutics, Inc.